Exotherm Curves: A Method for Obtaining Reproducible Curing Parameters for Radiation Polymerization of Vinyl-Divinyl Comonomers

Polymerization parameters, suitable for both monitoring and comparative studies on catalytic and radiation polymerization of MMA/divinyl comonomers, are readily derived from time/temperature exotherm records. By geometric solution of exotherm curves Gel Effect Point (GEP), polymerization rate coefficients in Activation (PRCI) and Acceleration (PRCII), and total dose (D) became available for kinetic studies. Individual components of the exotherm curve, such as reciprocal of time required to attain maximum on the exotherm curve, provide information on the overall rate of cure (ORC). Reciprocal of the time required to reach GEP characterizes the efficiency of cross-linking agents to cause onset of the gel effect phenomena in comonomer systems.Repeated measurements and statistical analyses of such data, derived from exotherms, show good reproducibility and a high degree of reliability, especially with systems exhibiting rather sharp maxima on the exotherm curve

Intraclonal Variation in Wood Density of Trembling Aspen in Alberta

Four trees from each of three putative clones of trembling aspen (Populus tremuloides Michx.) at one site in north-central Alberta were sampled to determine the patterns of wood density variation within stems and within clones. Sample disks were removed at five heights from each tree to examine variation among cardinal directions and across the southern radius at each height. Although only three clones were sampled, there were significant differences (0.05 level) among clones. Wood density tends to be high at the bottom of the tree, decreases to a minimum at midheight, then increases again near the top of the tree. In the radial direction, wood density is high near the pith (at all heights), decreases, then increases again in the mature wood zone (after rings 15-20+). Average wood density values within the twelve stems varied from 0.348 g/cc to 0.402 g/cc

qBounce: Systematic shifts of transition frequencies of gravitational states of ultra-cold neutrons using Ramsey gravity resonance spectroscopy

qBounce is using quantum states of ultra-cold neutrons in the gravitational field of the Earth to investigate gravitation in the micrometre range. We present current measurements taken in 2021 at the Institut Laue-Langevin (ILL) to determine energy differences of these states by mechanically induced transitions. This allows a determination of the local acceleration $g$ using a quantum measurement. The data presented here results in $g=9.8120(18) m/s^2$. The classical local value at the experiment is $g_c=9.8049 m/s^2$. We present an analysis of systematic effects that induces shifts of the transition frequency of order 100 mHz. The inferred value for $g$ at the experiment shows a systematic shift of $\delta g\approx3.9\sigma$

Farmer preferences for groundnut traits and varieties in West Africa: Cases of Mali, Niger and Nigeria.Working Paper Series no. 27

Participatory varietal selection trials were implemented in Mali, Niger and Nigeria and were used to assess farmers’ preferences for plant and seed traits of selected groundnut varieties. Using a panel of farmers in every country, plant and seed traits were assessed and found to be statistically associated with the varieties tested. Ordered probit models were used to identify plant and seed traits liked by panelists. Color of the leaves, maturity (short cycle), number of pods, pod size, constriction, pod yield, pod filling and taste were the important attributes explaining farmers ranking for varieties in Mali. In Niger, the color of the leaves, the number of pods per plant, pod filling, pod beak, and pod yield were the most important traits sought by farmers. In Nigeria, plant vigor, plant maturity, plant type, number of pods per plant, pod size, haulm yield and pod yield were the preferred traits. These traits should be used to identify varieties (from large germplasm collections) most likely to be adopted by farmers. Varieties with traits sought by farmers should be promoted and used to build sustainable seed supply systems. Attributes such as color of leaves, pod reticulation and pod beak tend to be overlooked and should be included in future breeding programs Ndjeunga J, Ntare BR, Abdoulaye A, Ibro A, Zarafi MA, Cisse Y, Moutari A, Kodio O, Echekwu CA, Mohammed SG and Micko

Baseline characteristics of patients in the reduction of events with darbepoetin alfa in heart failure trial (RED-HF)

<p>Aims: This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes.</p> <p>Methods and results: Key demographic, clinical, and laboratory findings, along with baseline treatment, are reported and compared with those of patients in other recent clinical trials in heart failure. Compared with other recent trials, RED-HF enrolled more elderly [mean age 70 (SD 11.4) years], female (41%), and black (9%) patients. RED-HF patients more often had diabetes (46%) and renal impairment (72% had an estimated glomerular filtration rate <60 mL/min/1.73 m2). Patients in RED-HF had heart failure of longer duration [5.3 (5.4) years], worse NYHA class (35% II, 63% III, and 2% IV), and more signs of congestion. Mean EF was 30% (6.8%). RED-HF patients were well treated at randomization, and pharmacological therapy at baseline was broadly similar to that of other recent trials, taking account of study-specific inclusion/exclusion criteria. Median (interquartile range) haemoglobin at baseline was 112 (106–117) g/L.</p> <p>Conclusion: The anaemic patients enrolled in RED-HF were older, moderately to markedly symptomatic, and had extensive co-morbidity.</p&gt

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Abstract BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups. CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo. (Funded by Amylin Pharmaceuticals; EXSCEL ClinicalTrials.gov number, NCT01144338 .)